Companies / AGN

ARGENICA THERAPEUTICS LIMITED

ASX:AGNPharmaceuticals, Biotechnology & Life Sciences
128.5M shares on issueASX (delayed) · as of 28 July 2026$0.16price · delayed$19.9Mmarket cap · indicative
B
Dilution grade

Runway 2–4 quarters

Cash runway3.7 quarters of funding
Share-count growth (24m)3.8%
Raise cadence (24m)0 cash raises
Options & rights overhang0.4% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

ARGENICA THERAPEUTICS LIMITED's ordinary share count was 128M as of July 2025, up 3.8% since June 2024. The company did not raise capital in the 24-month window reported. Options and rights on issue could convert into 500,000 new shares, equal to 0.4% of the current share count, none are in the money, and the nearest expiry is May 2027. At the June 2026 quarter the company reported A$5.9M in available cash, sufficient for about 3.7 quarters at its recent spending rate. There are no proposed securities issues (Appendix 3B) pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.4%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
3.7 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 128.5M per ASX (delayed) (28 July 2026).
128.2M128.3M128.4MDec 24Sept 25July 26

Cash runway

3.7 qtrs
Two to four quarters of funding at the recent spend rate.
$5.9M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
9 June 20263H · cancellationAGN : ORDINARY FULLY PAID128.5MAppendix 3H
20 Oct 20253G · unquotedAGN : ORDINARY FULLY PAID128.5MAppendix 3G
9 July 20252A · quoted issueAGN : ORDINARY FULLY PAID128.4MAppendix 2A
9 July 20253H · cancellationAGN : ORDINARY FULLY PAID128.1MAppendix 3H
9 July 20252A · quoted issueAGN : ORDINARY FULLY PAID128.1MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

0.4%
Total overhang · of current shares
0.0%
In the money · at current price
500k
Potential new shares
May 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
3 June 2025LIZ DALLIMOREOther352k——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026Investor Presentation - Techknow Conference
23 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
15 July 2026$PARG007 Shows Significant Neuroprotection in Concussion Study
10 June 2026Investor Webinar
10 June 2026Investor Presentation
10 June 2026$PARG007 (Xaranetide) Completes All Three FDA Requested Assays
9 June 2026$PWHO Confirms Xaranetide as INN for ARG-007
9 June 2026Notification of cessation of securities - AGN
25 May 2026Release of Securities from Voluntary Escrow
20 May 2026$PIND Application Advanced With Successful Completion of Assay
13 May 2026$PClinical Advisory Committee Established to Advance Phase 2b
28 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
15 Apr 2026Investor Presentation - Ignite Conference
25 Mar 2026$PPresentations at European Stroke Organisation Conference
16 Mar 2026$PArgenica Receives $3.97m R&D Tax Incentive Cash Rebate
10 Feb 2026$PHalf Yearly Report and Accounts
4 Feb 2026Investor Presentation - Euroz Hartleys Healthcare Conference
1 Feb 2026$PSuccessful Applicaton for EMA Paediatric Waiver
27 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
2 Jan 2026Final Director's Interest Notice

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.